Disease · MONDO_0006875
Comparisons in its trials120
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 120
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Generic Brinzolamide 1% Ophthalmic Suspension vs Azopt® 1% Ophthalmic Suspension: serious adverse events | 0 of 489 | 0 of 475 | 964 | NCT02512042 | Trial comparisons |
| Brinz/Brim vs Brinz+Brim: serious adverse events | 11 of 452 | 8 of 436 | 888 | NCT01309204 | Trial comparisons |
| Travoprost 0.003% vs TRAVATAN: serious adverse events | 5 of 442 | 7 of 421 | 863 | NCT01453855 | Trial comparisons |
| Bimatoprost 0.03% Eye Drops vs Latanoprost 0.005% Eye Drops: serious adverse events | 4 of 269 | 11 of 586 | 855 | NCT00541242 | Trial comparisons |
| Bimatoprost 0.01% Ophthalmic Solution vs Bimatoprost 0.03% Ophthalmic Solution: serious adverse events | 45 of 400 | 40 of 398 | 798 | NCT01298700 | Trial comparisons |
| Travoprost vs Latanoprost: serious adverse events | 5 of 363 | 7 of 363 | 726 | NCT00690794 | Trial comparisons |
| Travoprost vs Latanoprost: serious adverse events | 4 of 353 | 6 of 348 | 701 | NCT00761319 | Trial comparisons |
| PDP-716 vs Brimonidine Tartrate Ophthalmic Solution: deaths from any cause | 0 of 337 | 0 of 341 | 678 | NCT03450629 | Trial comparisons |
| PDP-716 vs Brimonidine Tartrate Ophthalmic Solution: serious adverse events | 1 of 337 | 3 of 341 | 678 | NCT03450629 | Trial comparisons |
| Tafluprost vs Timolol Maleate: serious adverse events | 2 of 320 | 7 of 323 | 643 | NCT01026831 | Trial comparisons |
| Brinzolamide 1% Ophthalmic Suspension vs Azopt 1% Ophthalmic Suspension: deaths from any cause | 0 of 320 | 0 of 318 | 638 | NCT03896633 | Trial comparisons |
| Brinzolamide 1% Ophthalmic Suspension vs Azopt 1% Ophthalmic Suspension: serious adverse events | 0 of 320 | 2 of 318 | 638 | NCT03896633 | Trial comparisons |
| BRIN-20-01 vs Azopt®: deaths from any cause | 0 of 297 | 0 of 300 | 597 | NCT05022004 | Trial comparisons |
| BRIN-20-01 vs Azopt®: serious adverse events | 0 of 297 | 1 of 300 | 597 | NCT05022004 | Trial comparisons |
| Bimatoprost 0.03% Formulation B Ophthalmic Solution vs Bimatoprost 0.03% Ophthalmic Solution: serious adverse events | 2 of 301 | 5 of 295 | 596 | NCT01099774 | Trial comparisons |
| OTX-TP (Sustained Release Travoprost) Intracanalicular Depot vs Placebo Vehicle (PV): deaths from any cause | 1 of 348 | 0 of 217 | 565 | NCT02914509 | Trial comparisons |
| OTX-TP (Sustained Release Travoprost) Intracanalicular Depot vs Placebo Vehicle (PV): Number of Participants With Serious Adverse Events | 7 of 348 | 6 of 217 | 565 | NCT02914509 | Trial comparisons |
| OTX-TP (Sustained Release Travoprost) Intracanalicular Depot vs Placebo Vehicle (PV): serious adverse events | 7 of 348 | 6 of 217 | 565 | NCT02914509 | Trial comparisons |
| Bimatoprost/Timolol Formulation A vs Bimatoprost/Timolol Fixed Combination Ophthalmic Solution: serious adverse events | 4 of 278 | 4 of 282 | 560 | NCT01177098 | Trial comparisons |
| Perrigo Active vs Reference Active: deaths from any cause | 0 of 249 | 0 of 246 | 495 | NCT04024072 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006875/comparisons